I was intrigued by the study by Tang et al1 on glycated albumin (GA) as a predictor for outcomes in patients with chronic kidney disease (CKD) within the Chronic Renal Insufficiency Cohort. Their findings linking higher GA levels to increased kidney and cardiovascular risks are commendable. However, I wish to highlight additional considerations regarding GA level modifiers.